Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1978 2
1980 1
1981 2
1982 1
1983 3
1985 1
1987 1
1989 1
1990 1
1991 1
1992 4
1993 1
1994 2
1995 4
1996 3
1997 4
1998 7
1999 12
2000 13
2001 14
2002 12
2003 20
2004 25
2005 24
2006 34
2007 54
2008 34
2009 56
2010 52
2011 64
2012 52
2013 54
2014 60
2015 58
2016 54
2017 52
2018 54
2019 44
2020 47
2021 58
2022 57
2023 49
2024 48
2025 15

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

1,015 results

Results by year

Filters applied: . Clear all
Page 1
Encorafenib, Binimetinib, and Cetuximab in BRAF V600E-Mutated Colorectal Cancer.
Kopetz S, Grothey A, Yaeger R, Van Cutsem E, Desai J, Yoshino T, Wasan H, Ciardiello F, Loupakis F, Hong YS, Steeghs N, Guren TK, Arkenau HT, Garcia-Alfonso P, Pfeiffer P, Orlov S, Lonardi S, Elez E, Kim TW, Schellens JHM, Guo C, Krishnan A, Dekervel J, Morris V, Calvo Ferrandiz A, Tarpgaard LS, Braun M, Gollerkeri A, Keir C, Maharry K, Pickard M, Christy-Bittel J, Anderson L, Sandor V, Tabernero J. Kopetz S, et al. Among authors: hong ys. N Engl J Med. 2019 Oct 24;381(17):1632-1643. doi: 10.1056/NEJMoa1908075. Epub 2019 Sep 30. N Engl J Med. 2019. PMID: 31566309 Clinical Trial.
Encorafenib Plus Cetuximab as a New Standard of Care for Previously Treated BRAF V600E-Mutant Metastatic Colorectal Cancer: Updated Survival Results and Subgroup Analyses from the BEACON Study.
Tabernero J, Grothey A, Van Cutsem E, Yaeger R, Wasan H, Yoshino T, Desai J, Ciardiello F, Loupakis F, Hong YS, Steeghs N, Guren TK, Arkenau HT, Garcia-Alfonso P, Elez E, Gollerkeri A, Maharry K, Christy-Bittel J, Kopetz S. Tabernero J, et al. Among authors: hong ys. J Clin Oncol. 2021 Feb 1;39(4):273-284. doi: 10.1200/JCO.20.02088. J Clin Oncol. 2021. PMID: 33503393 Free PMC article. Clinical Trial.
Mitochondrial DNA copy number variation in asthma risk, severity, and exacerbations.
Xu W, Hong YS, Hu B, Comhair SAA, Janocha AJ, Zein JG, Chen R, Meyers DA, Mauger DT, Ortega VE, Bleecker ER, Castro M, Denlinger LC, Fahy JV, Israel E, Levy BD, Jarjour NN, Moore WC, Wenzel SE, Gaston B, Liu C, Arking DE, Erzurum SC; National Heart, Lung, and Blood Institute (NHLBI) Severe Asthma Research Program and TOPMed mtDNA Working Group in NHLBI Trans-omics for Precision Medicine (TOPMed) Consortium. Xu W, et al. Among authors: hong ys. J Allergy Clin Immunol. 2024 Sep 3:S0091-6749(24)00906-0. doi: 10.1016/j.jaci.2024.08.022. Online ahead of print. J Allergy Clin Immunol. 2024. PMID: 39237012
Mitochondrial heteroplasmy improves risk prediction for myeloid neoplasms.
Hong YS, Pasca S, Shi W, Puiu D, Lake NJ, Lek M, Ru M, Grove ML, Prizment A, Joshu CE, Platz EA, Guallar E, Arking DE, Gondek LP. Hong YS, et al. Nat Commun. 2024 Nov 22;15(1):10133. doi: 10.1038/s41467-024-54443-3. Nat Commun. 2024. PMID: 39578475 Free PMC article.
Dysregulated CREB3 cleavage at the nuclear membrane induces karyoptosis-mediated cell death.
Lee GE, Bang G, Byun J, Lee CJ, Chen W, Jeung D, An HJ, Kang HC, Lee JY, Lee HS, Hong YS, Kim DJ, Keniry M, Kim JY, Choi JS, Fanto M, Cho SJ, Kim KD, Cho YY. Lee GE, et al. Among authors: hong ys. Exp Mol Med. 2024 Mar;56(3):686-699. doi: 10.1038/s12276-024-01195-1. Epub 2024 Mar 13. Exp Mol Med. 2024. PMID: 38480902 Free PMC article.
Olaparib with or without bevacizumab versus bevacizumab plus a fluoropyrimidine as maintenance therapy in advanced colorectal cancer: The randomized phase 3 LYNK-003 study.
Takashima A, García-Alfonso P, Manneh R, Beşen AA, Hong YS, Cuyle PJ, Yanez P, Burge M, Yoshino T, Kim TW, Cui K, Li C, Jain R, Adelberg D, Taieb J. Takashima A, et al. Among authors: hong ys. Eur J Cancer. 2024 Jul;205:114036. doi: 10.1016/j.ejca.2024.114036. Epub 2024 Mar 21. Eur J Cancer. 2024. PMID: 38749110 Free article. Clinical Trial.
Evaluation and management of lead exposure.
Kim HC, Jang TW, Chae HJ, Choi WJ, Ha MN, Ye BJ, Kim BG, Jeon MJ, Kim SY, Hong YS. Kim HC, et al. Among authors: hong ys. Ann Occup Environ Med. 2015 Dec 15;27:30. doi: 10.1186/s40557-015-0085-9. eCollection 2015. Ann Occup Environ Med. 2015. PMID: 26677413 Free PMC article. Review.
1,015 results